Predictive value of amino acids in the treatment of major depression with fluvoxamine
Massimo C. Mauri, Luigi Boscati, Lucia S. Volonteri, Marta E. Scalvini, C. P C Steinhilber, Valerio Laini, Federica Zamberlan
Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico
Sixteen outpatients (mean age ± SD 50.18 ± 11.55 years; 11 females and 5 males) affected by major depression without melancholia (DSM-IV) were included in the study. The control group consisted of 11 healthy volunteers (mean age ± SD 39.90 ± 13.39 years; 2 females and 9 males). Patients were treated with fluvoxamine (FVX) 100-300 mg daily. Clinical assessment was performed using the Hamilton Rating Scales for Anxiety and Depression (HRS-A; HRS-D) and the Clinical Global Impression Scale (CGI) at basal time (T0), after 4 weeks and after 8 weeks (T8). Plasma and platelet amino acid levels were determined at T0 in all the subjects and also at T8 in depressed patients. A significant clinical improvement was observed in depressed patients according to the HRS-A (p = 0.004), HRS-D (p = 0.008) and CGI (p = 0.002). A negative correlation (r = -0.53, p = 0.049) was found between platelet levels of valine and HRS-D improvement rate. Patients showed significantly higher tyrosine/large neutral amino acids (LNAAs) and lower tryptophan/LNAAs, ratios which could represent an index of good response to a serotonergic drug like FVX.
https://doi.org/10.1159/000054933
Psychology(all)
10.1159/000054933
Fingerprint Dive into the research topics of 'Predictive value of amino acids in the treatment of major depression with fluvoxamine'. Together they form a unique fingerprint.
Fluvoxamine Medicine & Life Sciences
Neutral Amino Acids Medicine & Life Sciences
Amino Acids Medicine & Life Sciences
Blood Platelets Medicine & Life Sciences
Serotonin Agents Medicine & Life Sciences
Valine Medicine & Life Sciences
Tryptophan Medicine & Life Sciences
Mauri, M. C., Boscati, L., Volonteri, L. S., Scalvini, M. E., Steinhilber, C. P. C., Laini, V., & Zamberlan, F. (2001). Predictive value of amino acids in the treatment of major depression with fluvoxamine. Neuropsychobiology, 44(3), 134-138. https://doi.org/10.1159/000054933
Predictive value of amino acids in the treatment of major depression with fluvoxamine. / Mauri, Massimo C.; Boscati, Luigi; Volonteri, Lucia S.; Scalvini, Marta E.; Steinhilber, C. P C; Laini, Valerio; Zamberlan, Federica.
In: Neuropsychobiology, Vol. 44, No. 3, 2001, p. 134-138.
Mauri, MC, Boscati, L, Volonteri, LS, Scalvini, ME, Steinhilber, CPC, Laini, V & Zamberlan, F 2001, 'Predictive value of amino acids in the treatment of major depression with fluvoxamine', Neuropsychobiology, vol. 44, no. 3, pp. 134-138. https://doi.org/10.1159/000054933
Mauri MC, Boscati L, Volonteri LS, Scalvini ME, Steinhilber CPC, Laini V et al. Predictive value of amino acids in the treatment of major depression with fluvoxamine. Neuropsychobiology. 2001;44(3):134-138. https://doi.org/10.1159/000054933
Mauri, Massimo C. ; Boscati, Luigi ; Volonteri, Lucia S. ; Scalvini, Marta E. ; Steinhilber, C. P C ; Laini, Valerio ; Zamberlan, Federica. / Predictive value of amino acids in the treatment of major depression with fluvoxamine. In: Neuropsychobiology. 2001 ; Vol. 44, No. 3. pp. 134-138.
@article{6fc2915b51ad4f1fb0f78878bcea967b,
title = "Predictive value of amino acids in the treatment of major depression with fluvoxamine",
abstract = "Sixteen outpatients (mean age ± SD 50.18 ± 11.55 years; 11 females and 5 males) affected by major depression without melancholia (DSM-IV) were included in the study. The control group consisted of 11 healthy volunteers (mean age ± SD 39.90 ± 13.39 years; 2 females and 9 males). Patients were treated with fluvoxamine (FVX) 100-300 mg daily. Clinical assessment was performed using the Hamilton Rating Scales for Anxiety and Depression (HRS-A; HRS-D) and the Clinical Global Impression Scale (CGI) at basal time (T0), after 4 weeks and after 8 weeks (T8). Plasma and platelet amino acid levels were determined at T0 in all the subjects and also at T8 in depressed patients. A significant clinical improvement was observed in depressed patients according to the HRS-A (p = 0.004), HRS-D (p = 0.008) and CGI (p = 0.002). A negative correlation (r = -0.53, p = 0.049) was found between platelet levels of valine and HRS-D improvement rate. Patients showed significantly higher tyrosine/large neutral amino acids (LNAAs) and lower tryptophan/LNAAs, ratios which could represent an index of good response to a serotonergic drug like FVX.",
keywords = "Amino acids, Fluvoxamine, Major depression",
author = "Mauri, {Massimo C.} and Luigi Boscati and Volonteri, {Lucia S.} and Scalvini, {Marta E.} and Steinhilber, {C. P C} and Valerio Laini and Federica Zamberlan",
doi = "10.1159/000054933",
journal = "Neuropsychobiology",
T1 - Predictive value of amino acids in the treatment of major depression with fluvoxamine
AU - Mauri, Massimo C.
AU - Boscati, Luigi
AU - Volonteri, Lucia S.
AU - Scalvini, Marta E.
AU - Steinhilber, C. P C
AU - Laini, Valerio
AU - Zamberlan, Federica
N2 - Sixteen outpatients (mean age ± SD 50.18 ± 11.55 years; 11 females and 5 males) affected by major depression without melancholia (DSM-IV) were included in the study. The control group consisted of 11 healthy volunteers (mean age ± SD 39.90 ± 13.39 years; 2 females and 9 males). Patients were treated with fluvoxamine (FVX) 100-300 mg daily. Clinical assessment was performed using the Hamilton Rating Scales for Anxiety and Depression (HRS-A; HRS-D) and the Clinical Global Impression Scale (CGI) at basal time (T0), after 4 weeks and after 8 weeks (T8). Plasma and platelet amino acid levels were determined at T0 in all the subjects and also at T8 in depressed patients. A significant clinical improvement was observed in depressed patients according to the HRS-A (p = 0.004), HRS-D (p = 0.008) and CGI (p = 0.002). A negative correlation (r = -0.53, p = 0.049) was found between platelet levels of valine and HRS-D improvement rate. Patients showed significantly higher tyrosine/large neutral amino acids (LNAAs) and lower tryptophan/LNAAs, ratios which could represent an index of good response to a serotonergic drug like FVX.
AB - Sixteen outpatients (mean age ± SD 50.18 ± 11.55 years; 11 females and 5 males) affected by major depression without melancholia (DSM-IV) were included in the study. The control group consisted of 11 healthy volunteers (mean age ± SD 39.90 ± 13.39 years; 2 females and 9 males). Patients were treated with fluvoxamine (FVX) 100-300 mg daily. Clinical assessment was performed using the Hamilton Rating Scales for Anxiety and Depression (HRS-A; HRS-D) and the Clinical Global Impression Scale (CGI) at basal time (T0), after 4 weeks and after 8 weeks (T8). Plasma and platelet amino acid levels were determined at T0 in all the subjects and also at T8 in depressed patients. A significant clinical improvement was observed in depressed patients according to the HRS-A (p = 0.004), HRS-D (p = 0.008) and CGI (p = 0.002). A negative correlation (r = -0.53, p = 0.049) was found between platelet levels of valine and HRS-D improvement rate. Patients showed significantly higher tyrosine/large neutral amino acids (LNAAs) and lower tryptophan/LNAAs, ratios which could represent an index of good response to a serotonergic drug like FVX.
KW - Amino acids
KW - Fluvoxamine
KW - Major depression
U2 - 10.1159/000054933
DO - 10.1159/000054933
JO - Neuropsychobiology
JF - Neuropsychobiology